期刊论文详细信息
Breast Cancer Research
Assessment of the proliferative, apoptotic and cellular renovation indices of the human mammary epithelium during the follicular and luteal phases of the menstrual cycle
Afonso CP Nazário3  Edmund C Baracat3  Geraldo R Lima3  Luiz Gerk de Azevedo Quadros3  Roberto Falzoni2  Carolina M Maier1  Maria Alicia H Navarrete3 
[1] Department of Neurosurgery, Stanford University School of Medicine, Stanford, California, USA;APC Pathology, São Paulo, Brazil;Department of Gyneology, Mastology Division, Federal University of São Paulo, São Paulo, Brazil
关键词: TdT-mediated dUTP nick end labeling;    menstrual cycle;    mammary gland;    Ki-67;    apoptosis;   
Others  :  1114955
DOI  :  10.1186/bcr994
 received in 2004-06-06, accepted in 2004-12-20,  发布年份 2005
PDF
【 摘 要 】

Introduction

During the menstrual cycle, the mammary gland goes through sequential waves of proliferation and apoptosis. In mammary epithelial cells, hormonal and non-hormonal factors regulate apoptosis. To determine the cyclical effects of gonadal steroids on breast homeostasis, we evaluated the apoptotic index (AI) determined by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining in human mammary epithelial cells during the spontaneous menstrual cycle and correlated it with cellular proliferation as determined by the expression of Ki-67 during the same period.

Methods

Normal breast tissue samples were obtained from 42 randomly selected patients in the proliferative (n = 21) and luteal (n = 21) phases. Menstrual cycle phase characterization was based on the date of the last and subsequent menses, and on progesterone serum levels obtained at the time of biopsy.

Results

The proliferation index (PI), defined as the number of Ki-67-positive nuclei per 1,000 epithelial cells, was significantly larger in the luteal phase (30.46) than in the follicular phase (13.45; P = 0.0033). The AI was defined as the number of TUNEL-positive cells per 1,000 epithelial cells. The average AI values in both phases of the menstrual cycle were not statistically significant (P = 0.21). However, the cell renewal index (CRI = PI/AI) was significantly higher in the luteal phase (P = 0.033). A significant cyclical variation of PI, AI and CRI was observed. PI and AI peaks occurred on about the 24th day of the menstrual cycle, whereas the CRI reached higher values on the 28th day.

Conclusions

We conclude that proliferative activity is dependent mainly on hormonal fluctuations, whereas apoptotic activity is probably regulated by hormonal and non-hormonal factors.

【 授权许可】

   
2005 Navarrete et al. licensee BioMed Central Ltd.

【 预 览 】
附件列表
Files Size Format View
20150205030909233.pdf 565KB PDF download
Figure 2. 80KB Image download
Figure 1. 83KB Image download
【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】
  • [1]Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics, 2000. CA Cancer J Clin 2000, 50:7-33.
  • [2]Wellings SR, Jensen HM, Marcum RG: An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J Natl Cancer Inst 1975, 55:231-273.
  • [3]Masters JR, Sangster K, Smith II: Hormonal sensitivity of human breast tumors in vitro: pentose-shunt activity. Cancer 1977, 39:1978-1980.
  • [4]Meyer JS: Cell proliferation in normal human breast ducts, fibroadenomas, and other ductal hyperplasias measured by nuclear labeling with tritiated thymidine. Effects of menstrual phase, age, and oral contraceptive hormones. Hum Pathol 1977, 8:67-81.
  • [5]Ferguson DJ, Anderson TJ: Morphological evaluation of cell turnover in relation to the menstrual cycle in the 'resting' human breast. Br J Cancer 1981, 44:177-181.
  • [6]Anderson TJ, Ferguson DJ, Raab GM: Cell turnover in the 'resting' human breast: influence of parity, contraceptive pill, age and laterality. Br J Cancer 1982, 46:376-382.
  • [7]Going JJ, Anderson TJ, Battersby S, MacIntyre CC: Proliferative and secretory activity in human breast during natural and artificial menstrual cycles. Am J Pathol 1988, 130:193-204.
  • [8]Potten CS, Watson RJ, Williams GT, Tickle S, Roberts SA, Harris M, Howell A: The effect of age and menstrual cycle upon proliferative activity of the normal human breast. Br J Cancer 1988, 58:163-170.
  • [9]Pike MC, Spicer DV, Dahmoush L, Press MF: Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993, 15:17-35.
  • [10]Nazario AC, De Lima GR, Simoes MJ, Novo NF: Cell kinetics of the human mammary lobule during the proliferative and secretory phase of the menstrual cycle. Bull Assoc Anat (Nancy) 1995, 79:23-27.
  • [11]Mainwaring PN, Ellis PA, Detre S, Smith IE, Dowsett M: Comparison of in situ methods to assess DNA cleavage in apoptotic cells in patients with breast cancer. J Clin Pathol 1998, 51:34-37.
  • [12]Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984, 133:1710-1715.
  • [13]Israel R, Mishell DR Jr, Stone SC, Thorneycroft IH, Moyer DL: Single luteal phase serum progesterone assay as an indicator of ovulation. Am J Obstet Gynecol 1972, 112:1043-1046.
  • [14]Bassler R: The morphology of hormone induced structural changes in the female breast. Curr Top Pathol 1970, 53:1-89.
  • [15]Izquierdo JN, Gibbs SJ: Turnover of cell-renewing populations undergoing circadian rhythms in cell proliferation. Cell Tissue Kinet 1974, 7:99-111.
  • [16]Masters JR, Drife JO, Scarisbrick JJ: Cyclic Variation of DNA synthesis in human breast epithelium. J Natl Cancer Inst 1977, 58:1263-1265.
  • [17]Fanger H, Ree HJ: Cyclic changes of human mammary gland epithelium in relation to menstrual cycle – an ultrastructural study. Cancer 1974, 34:571-585.
  • [18]Andres AC, Strange R: Apoptosis in the estrous and menstrual cycles. J Mammary Gland Biol Neoplasia 1999, 4:221-228.
  • [19]Anderson TJ: Pathological studies of apoptosis in the normal breast. Endocr Relat Cancer 1999, 6:9-12.
  • [20]Longacre TA, Bartow SA: A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am J Surg Pathol 1986, 10:382-393.
  • [21]Flaxman BA, Lasfargues EY: Hormone-independent DNA synthesis by epithelial cells of adult human mammary gland in organ culture. Proc Soc Exp Biol Med 1973, 143:371-374.
  • [22]Vogel PM, Georgiade NG, Fetter BF, Vogel FS, McCarty KS Jr: The correlation of histologic changes in the human breast with the menstrual cycle. Am J Pathol 1981, 104:23-34.
  • [23]Hassan HI, Walker RA: Decreased apoptosis in non-involved tissue from cancer-containing breasts. J Pathol 1998, 184:258-264.
  • [24]Feuerhake F, Sigg W, Hofter EA, Dimpfl T, Welsch U: Immunohistochemical analysis of Bcl-2 and Bax expression in relation to cell turnover and epithelial differentiation markers in the non-lactating human mammary gland epithelium. Cell Tissue Res 2000, 299:47-58.
  • [25]Ramakrishnan R, Khan SA, Badve S: Morphological changes in breast tissue with menstrual cycle. Mod Pathol 2002, 15:1348-1356.
  • [26]Anderson TJ, Battersby S, King RJ, McPherson K, Going JJ: Oral contraceptive use influences resting breast proliferation. Hum Pathol 1989, 20:1139-1144.
  • [27]Brown DC, Gatter KC: Monoclonal antibody Ki-67: its use in histopathology. Histopathology 1990, 17:489-503.
  • [28]Aakvaag A, Utaaker E, Thorsen T, Lea OA, Lahooti H: Growth control of human mammary cancer cells (MCF-7 cells) in culture: effect of estradiol and growth factors in serum-containing medium. Cancer Res 1990, 50:7806-7810.
  • [29]Kumar V, Green S, Stack G, Berry M, Jin JR, Chambon P: Functional domains of the human estrogen receptor. Cell 1987, 51:941-951.
  • [30]Katzenellenbogen BS, Kendra KL, Norman MJ, Berthois Y: Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res 1987, 47:4355-4360.
  • [31]Petersen OW, Hoyer PE, van Deurs B: Frequency and distribution of estrogen receptor-positive cells in normal, nonlactating human breast tissue. Cancer Res 1987, 47:5748-5751.
  • [32]Jacquemier JD, Hassoun J, Torrente M, Martin PM: Distribution of estrogen and progesterone receptors in healthy tissue adjacent to breast lesions at various stages – immunohistochemical study of 107 cases. Breast Cancer Res Treat 1990, 15:109-117.
  • [33]McGuire W, Carbone P, Vollmer R: Estrogen Receptors in Human Breast Cancer. New York: Raven Press; 1975.
  • [34]Dickson RB, Lippman ME: Growth factors in breast cancer. Endocr Rev 1995, 16:559-589.
  • [35]Wittliff JL: Steroid-hormone receptors in breast cancer. Cancer 1984, 53(3 Suppl):630-643.
  • [36]Watts CK, Handel ML, King RJ, Sutherland RL: Oestrogen receptor gene structure and function in breast cancer. J Steroid Biochem Mol Biol 1992, 41:529-536.
  • [37]Bates SE, Valverius EM, Ennis BW, Bronzert DA, Sheridan JP, Stampfer MR, Mendelsohn J, Lippman ME, Dickson RB: Expression of the transforming growth factor-alpha/epidermal growth factor receptor pathway in normal human breast epithelial cells. Endocrinology 1990, 126:596-607.
  • [38]Dell'Aquila ML, Pigott DA, Bonaquist DL, Gaffney EV: A factor from plasma-derived human serum that inhibits the growth of the mammary cell line MCF-7: characterization and purification. J Natl Cancer Inst 1984, 72:291-298.
  • [39]Soto AM, Sonnenschein C: Cell proliferation of estrogen-sensitive cells: the case for negative control. Endocr Rev 1987, 8:44-52.
  • [40]Hall JM, Couse JF, Korach KS: The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 2001, 276:36869-36872.
  • [41]Clarke RB, Howell A, Potten CS, Anderson E: Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 1997, 57:4987-4991.
  • [42]Means AR, O'Malley BW: Mechanism of estrogen action: early transcriptional and translational events. Metabolism 1972, 21:357-370.
  • [43]Katzenellenbogen BS, Katzenellenbogen JA: Biomedicine. Defining the 'S' in SERMs. Science 2002, 295:2380-2381.
  • [44]Mulac-Jericevic B, Mullinax RA, DeMayo FJ, Lydon JP, Conneely OM: Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. Science 2000, 289:1751-1754.
  • [45]McDonnell DP, Norris JD: Connections and regulation of the human estrogen receptor. Science 2002, 296:1642-1644.
  • [46]Reed JC: Balancing cell life and death: Bax, apoptosis, and breast cancer. J Clin Invest 1996, 97:2403-2404.
  • [47]Potten CS: What is an apoptotic index measuring? A commentary. Br J Cancer 1996, 74:1743-1748.
  • [48]Allan DJ, Howell A, Roberts SA, Williams GT, Watson RJ, Coyne JD, Clarke RB, Laidlaw IJ, Potten CS: Reduction in apoptosis relative to mitosis in histologically normal epithelium accompanies fibrocystic change and carcinoma of the premenopausal human breast. J Pathol 1992, 167:25-32.
  • [49]Fata JE, Chaudhary V, Khokha R: Cellular turnover in the mammary gland is correlated with systemic levels of progesterone and not 17β-estradiol during the estrous cycle. Biol Reprod 2001, 65:680-688.
  • [50]Ferrieres G, Cuny M, Simony-Lafontaine J, Jacquemier J, Rouleau C, Guilleux F, Grenier J, Rouanet P, Pujol H, Jeanteur P, et al.: Variation of bcl-2 expression in breast ducts and lobules in relation to plasma progesterone levels: overexpression and absence of variation in fibroadenomas. J Pathol 1997, 183:204-211.
  • [51]Sabourin JC, Martin A, Baruch J, Truc JB, Gompel A, Poitout P: bcl-2 expression in normal breast tissue during the menstrual cycle. Int J Cancer 1994, 59:1-6.
  • [52]Gompel A, Martin A, Simon P, Schoevaert D, Plu-Bureau G, Hugol D, Audouin J, Leygue E, Truc JB, Poitout P: Epidermal growth factor receptor and c-erbB-2 expression in normal breast tissue during the menstrual cycle. Breast Cancer Res Treat 1996, 38:227-235.
  • [53]Scholzen T, Gerdes J: The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000, 182:311-322.
  文献评价指标  
  下载次数:75次 浏览次数:13次